DAFNA Capital Management LLC
LOS ANGELES, CA · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$468.1M2026 Q3
Positions87
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.57.9%
What Changed This Quarter?
Top Holdings
RVMD
Revolution Medicines
21.4%
ATRC
AtriCure
6.3%
CMPS
COMPASS Pathways
5.7%
XBI
SPDR S&P Biotech
5.1%
NKTR
Nektar Therapeutics
4.2%
IDYA
IDEAYA Biosciences
3.6%
STXS
Stereotaxis
3.6%
DNLI
Denali Therapeutics
3.3%
New / Increased
4 new · 17 increased
BBOTNEW
Bridgebio Oncology Therapeutics
0.2%
PYXSNEW
Pyxis Oncology
0.2%
QNRXNEW
Quoin Pharmaceuticals
0.1%
KZIANEW
Kazia Therapeutics
0.0%
RAPP
Rapport Therapeutics
1.0%
+89.2%
NGNE
Neurogene
0.9%
+69.1%
EPRX
Eupraxia Pharmaceuticals
0.8%
+79.3%
CMPS
Compass Pathways
5.7%
+6.2%
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.